Anti-IL12B/ CLMF/ CLMF2 functional antibody

Anti-IL12B/ CLMF/ CLMF2 functional antibody for cell culture, ELISA & in-vivo assay

Target products collectionGo to IL12B/IL12B products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-T95385-Ab-1/ GM-Tg-hg-T95385-Ab-2Anti-Human IL12B monoclonal antibodyHuman
GM-Tg-rg-T95385-Ab-1/ GM-Tg-rg-T95385-Ab-2Anti-Rat IL12B monoclonal antibodyRat
GM-Tg-mg-T95385-Ab-1/ GM-Tg-mg-T95385-Ab-2Anti-Mouse IL12B monoclonal antibodyMouse
GM-Tg-cynog-T95385-Ab-1/ GM-Tg-cynog-T95385-Ab-2Anti-Cynomolgus/ Rhesus macaque IL12B monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-T95385-Ab-1/ GM-Tg-felg-T95385-Ab-2Anti-Feline IL12B monoclonal antibodyFeline
GM-Tg-cang-T95385-Ab-1/ GM-Tg-cang-T95385-Ab-2Anti-Canine IL12B monoclonal antibodyCanine
GM-Tg-bovg-T95385-Ab-1/ GM-Tg-bovg-T95385-Ab-2Anti-Bovine IL12B monoclonal antibodyBovine
GM-Tg-equg-T95385-Ab-1/ GM-Tg-equg-T95385-Ab-2Anti-Equine IL12B monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-T95385-Ab-1/ GM-Tg-hg-T95385-Ab-2; GM-Tg-rg-T95385-Ab-1/ GM-Tg-rg-T95385-Ab-2;
GM-Tg-mg-T95385-Ab-1/ GM-Tg-mg-T95385-Ab-2; GM-Tg-cynog-T95385-Ab-1/ GM-Tg-cynog-T95385-Ab-2;
GM-Tg-felg-T95385-Ab-1/ GM-Tg-felg-T95385-Ab-2; GM-Tg-cang-T95385-Ab-1/ GM-Tg-cang-T95385-Ab-2;
GM-Tg-bovg-T95385-Ab-1/ GM-Tg-bovg-T95385-Ab-2; GM-Tg-equg-T95385-Ab-1/ GM-Tg-equg-T95385-Ab-2
Products NameAnti-IL12B monoclonal antibody
Formatmab
Target NameIL12B
Protein Sub-locationSecreted Protein/Potential Cytokines
Category of antibodyFACS/Biofunctional Antibody, Therapeutics Target antibody, Cytokine antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-IL12B benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation Lyophilized from sterile PBS, PH 7.4
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    BiosimilarGMP-Bios-ab-605Pre-Made Ustekinumab biosimilar, Whole mAb, Anti-IL12B Antibody: Anti-CLMF/CLMF2/IL-12B/IMD28/IMD29/NKSF/NKSF2 therapeutic antibody
    BiosimilarGMP-Bios-ab-081Pre-Made Briakinumab biosimilar, Whole mAb, Anti-IL12B Antibody: Anti-CLMF/CLMF2/IL-12B/IMD28/IMD29/NKSF/NKSF2 therapeutic antibody
    BiosimilarGMP-Bios-ab-162Pre-Made Ebdarokimab biosimilar, Whole mAb, Anti-IL12B Antibody: Anti-CLMF/CLMF2/IL-12B/IMD28/IMD29/NKSF/NKSF2 therapeutic antibody
    Target AntigenGM-Tg-g-T95385-Ag-1Recombinant multi-species IL12B/ CLMF/ CLMF2 protein
    CytokineGM-Tg-g-T95385-Ag-1Interleukin 12b (IL12B) protein
    ORF Viral VectorpGMLP000740human IL12B Lentivirus plasmid
    ORF Viral VectorvGMLP000740human IL12B Lentivirus particle


    Target information

    Target IDGM-T95385
    Target NameIL12B
    Gene ID3593,16160,64546,694747,403976,768273,281857,100034222
    Gene Symbol and SynonymsCLMF,CLMF2,IL-12.p40,IL-12B,Il-12p40,Il12,IL12B,Il12p40,IMD28,IMD29,NKSF,NKSF2,p40
    Uniprot AccessionP29460,P48095,Q28268,O02744,P46282,Q9XSQ5
    Uniprot Entry NameIL12B_HUMAN,IL12B_MACMU,IL12B_FELCA,IL12B_CANLF,IL12B_BOVIN,IL12B_HORSE
    Protein Sub-locationSecreted Protein/Potential Cytokines
    CategoryTherapeutics Target, Immuno-oncology Target, INN Index, Cytokine Target
    DiseaseCancer
    Gene EnsemblENSG00000113302
    Target ClassificationCheckpoint-Immuno Oncology, Tumor-associated antigen (TAA)

    The target: IL12B, gene name: IL12B, also named as CLMF, CLMF2, IL-12B, IMD28, IMD29, NKSF, NKSF2. This gene encodes a subunit of interleukin 12, a cytokine that acts on T and natural killer cells, and has a broad array of biological activities. Interleukin 12 is a disulfide-linked heterodimer composed of the 40 kD cytokine receptor like subunit encoded by this gene, and a 35 kD subunit encoded by IL12A. This cytokine is expressed by activated macrophages that serve as an essential inducer of Th1 cells development. This cytokine has been found to be important for sustaining a sufficient number of memory/effector Th1 cells to mediate long-term protection to an intracellular pathogen. Overexpression of this gene was observed in the central nervous system of patients with multiple sclerosis (MS), suggesting a role of this cytokine in the pathogenesis of the disease. The promoter polymorphism of this gene has been reported to be associated with the severity of atopic and non-atopic asthma in children. [provided by RefSeq, Jul 2008].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.